Heidi Villalba
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Heidi Villalba has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Abraham Al-Ahmad
Department of Pharmaceutical Sciences, Texas Tech University Health Sciences Center - Jerry H. Hodge School of Pharmacy, Amarillo, TX, USA.
1 shared publication - Adarsh Nambiar
Department of Pharmaceutical Sciences, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, USA
1 shared publication - Derek Barthels
Department of Pharmaceutical Sciences, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, USA
1 shared publication - Heba A. Ewida
Department of Pharmacology and Biochemistry, Faculty of Pharmaceutical Sciences & Pharmaceutical Industries, Future University in Egypt, 12311 Cairo, Egypt
1 shared publication - Hiranmoy Das
Department of Pharmaceutical Sciences, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106-1712, USA
1 shared publication - Mahmoud Salama Ahmed
Department of Pharmaceutical Sciences, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA
1 shared publication
Latest Publications
- Open Access
Fatty Acid Metabolism Rewires Glioblastoma Progression and Treg-Mediated Immune Resistance
Glioblastoma (GBM) is one of the most aggressive and treatment-resistant cancers, shaped by a tumor microenvironment (TME) that is both metabolically demanding and strongly immunosuppressive. GBM relies heavily on fatty acid (FA) metabolism to sustain growth of rapidly dividing tumor cells and survive metabolic stress. GBM cells enhance lipid uptake, activate sterol regulatory element-binding protein 1 (SREBP-1)-driven lipogenesis, store excess lipids in droplets to prevent toxicity, and depend on fatty acid oxidation (FAO) to generate adenosine triphosphate (ATP) and maintain redox balance, particularly under nutrient-limited conditions. GBM TME is also consistently enriched with regulatory T cells (Tregs), which maintain suppressive activity despite the nutrient restrictions that impair effector T cells (Teffs). In hypoxia and nutrient limitation within the TME, Tregs can adapt by using FAO, lactate oxidation, and OXPHOS, supported by forkhead box P3 (Foxp3)-dependent metabolic programming, cluster of differentiation 36 (CD36)-mediated FA uptake, and hypoxia-related signals. At the same time, programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) signaling reduces glycolytic activity in Teffs and contributes to metabolic dysfunction, while also supporting the stability of oxidative metabolism in Tregs. Evidence from pre-clinical and clinical studies suggests a possible association between Treg enrichment in GBM and reduced responsiveness to immune checkpoint inhibitors (ICIs), although this relationship is not yet fully defined. Overall, current findings point to FA metabolism as a shared metabolic axis that supports both tumor progression and Treg-mediated immune resistance. Targeting lipid-driven pathways may offer an opportunity to disrupt these advantages and improve the effectiveness of existing immunotherapies for GBM.
Open AccessFatty Acid Metabolism Rewires Glioblastoma Progression and Treg-Mediated Immune Resistance
Glioblastoma (GBM) is one of the most aggressive and treatment-resistant cancers, shaped by a tumor microenvironment (TME) that is both metabolically demanding and strongly immunosuppressive. GBM relies heavily on fatty acid (FA) metabolism to sustain growth of rapidly dividing tumor cells and survive metabolic stress. GBM cells enhance lipid uptake, activate sterol regulatory element-binding protein 1 (SREBP-1)-driven lipogenesis, store excess lipids in droplets to prevent toxicity, and depend on fatty acid oxidation (FAO) to generate adenosine triphosphate (ATP) and maintain redox balance, particularly under nutrient-limited conditions. GBM TME is also consistently enriched with regulatory T cells (Tregs), which maintain suppressive activity despite the nutrient restrictions that impair effector T cells (Teffs). In hypoxia and nutrient limitation within the TME, Tregs can adapt by using FAO, lactate oxidation, and OXPHOS, supported by forkhead box P3 (Foxp3)-dependent metabolic programming, cluster of differentiation 36 (CD36)-mediated FA uptake, and hypoxia-related signals. At the same time, programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) signaling reduces glycolytic activity in Teffs and contributes to metabolic dysfunction, while also supporting the stability of oxidative metabolism in Tregs. Evidence from pre-clinical and clinical studies suggests a possible association between Treg enrichment in GBM and reduced responsiveness to immune checkpoint inhibitors (ICIs), although this relationship is not yet fully defined. Overall, current findings point to FA metabolism as a shared metabolic axis that supports both tumor progression and Treg-mediated immune resistance. Targeting lipid-driven pathways may offer an opportunity to disrupt these advantages and improve the effectiveness of existing immunotherapies for GBM.
- 6 October 2022
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 43 (5) , 2105-2127
Dental Pulp-Derived Stem Cells Preserve Astrocyte Health During Induced Gliosis by Modulating Mitochondrial Activity and Functions
Astrocytes have been implicated in the onset and complication of various central nervous system (CNS) injuries and disorders. Uncontrolled astrogliosis (gliosis), while a necessary process for recovery after CNS trauma, also causes impairments in CNS performance and functions. The ability to preserve astrocyte health and better regulate the gliosis process could play a major role in controlling damage in the aftermath of acute insults and during chronic dysfunction. Here in, we demonstrate the ability of dental pulp-derived stem cells (DPSCs) in protecting the health of astrocytes during induced gliosis. First of all, we have characterized the expression of genes in primary astrocytes that are relevant to the pathological conditions of CNS by inducing gliosis. Subsequently, we found that astrocytes co-cultured with DPSCs reduced ROS production, NRF2 and GCLM expressions, mitochondrial membrane potential, and mitochondrial functions compared to the astrocytes that were not co-cultured with DPSCs in gliosis condition. In addition, hyperactive autophagy was also decreased in astrocytes that were co-cultured with DPSCs compared to the astrocytes that were not co-cultured with DPSCs during gliosis. This reversal and mitigation of gliosis in astrocytes were partly due to induction of neurogenesis in DPSCs through enhanced expressions of the neuronal genes like GFAP, NeuN, and Synapsin in DPSCs and by secretion of higher amounts of neurotropic factors, such as BDNF, GDNF, and TIMP-2. Protein–Protein docking analysis suggested that BDNF and GDNF can bind with CSPG4 and block the downstream signaling. Together these findings demonstrate novel functions of DPSCs to preserve astrocyte health during gliosis. Graphical Abstract
- 6 October 2022
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 43 (5) , 2105-2127
Dental Pulp-Derived Stem Cells Preserve Astrocyte Health During Induced Gliosis by Modulating Mitochondrial Activity and Functions
Astrocytes have been implicated in the onset and complication of various central nervous system (CNS) injuries and disorders. Uncontrolled astrogliosis (gliosis), while a necessary process for recovery after CNS trauma, also causes impairments in CNS performance and functions. The ability to preserve astrocyte health and better regulate the gliosis process could play a major role in controlling damage in the aftermath of acute insults and during chronic dysfunction. Here in, we demonstrate the ability of dental pulp-derived stem cells (DPSCs) in protecting the health of astrocytes during induced gliosis. First of all, we have characterized the expression of genes in primary astrocytes that are relevant to the pathological conditions of CNS by inducing gliosis. Subsequently, we found that astrocytes co-cultured with DPSCs reduced ROS production, NRF2 and GCLM expressions, mitochondrial membrane potential, and mitochondrial functions compared to the astrocytes that were not co-cultured with DPSCs in gliosis condition. In addition, hyperactive autophagy was also decreased in astrocytes that were co-cultured with DPSCs compared to the astrocytes that were not co-cultured with DPSCs during gliosis. This reversal and mitigation of gliosis in astrocytes were partly due to induction of neurogenesis in DPSCs through enhanced expressions of the neuronal genes like GFAP, NeuN, and Synapsin in DPSCs and by secretion of higher amounts of neurotropic factors, such as BDNF, GDNF, and TIMP-2. Protein–Protein docking analysis suggested that BDNF and GDNF can bind with CSPG4 and block the downstream signaling. Together these findings demonstrate novel functions of DPSCs to preserve astrocyte health during gliosis. Graphical Abstract
- Open Access
- 1 April 2019
- Published by Wiley in The FASEB Journal
- Vol. 33 (S1) , 120.3
Determining the effect of the WNT/b‐catenin pathway on the ischemic blood‐brain barrier in vitro and in vivo
The blood‐brain barrier (BBB) is a selectively permeable barrier made up of tight junctions formed by endothelial cells that separates the circulating blood from the brain extracellular fluid. The primary function of the BBB is to limit the movement of xenobiotics from the blood to the brain. In the event of an ischemic stroke, the BBB opens allowing water and ions to enter the brain, leading to excitotoxicity and edema formation. Targeting such opening of the barrier following ischemic stroke has become a focus in current stroke studies. It has been shown that the Wnt/b‐catenin pathway is important for barrier formation during embryonic development, therefore, we hypothesized that activation of this pathway following ischemic stroke would attenuate barrier dysfunction. Brain microvascular endothelial cells (BMECs) derived from iPSCs were cultured and placed in ischemic stress for 6hrs, followed by an 18‐hour period of re‐oxygenation. Wnt small molecule activators (CHIR99021 and SB‐216763) and inhibitors (XAV939, IWP‐4, IWR‐1) were introduced at different time points of differentiation, during ischemia, and during re‐oxygenation. Transendothelial Electrical Resistance (TEER) and permeability were performed to assess barrier integrity following re‐oxygenation. For in vivo studies, C57BL mice were subjected to one‐hour ischemia by MCAO. At the time of re‐oxygenation, mice were dosed with CHIR99021 (IP; 30mg/kg). 24‐hours post‐MCAO, TTC staining on brains was performed to determine infarct size and edema ratio. The results of the in vitro studies have shown that activation of the Wnt pathway during re‐oxygenation results in increased barrier function, suggesting that the Wnt pathway is a potential target for post‐stroke therapy. This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .
- 1 April 2019
- Published by Wiley in The FASEB Journal
- Vol. 33 (S1) , 120.3
Open AccessDetermining the effect of the WNT/b‐catenin pathway on the ischemic blood‐brain barrier in vitro and in vivo
The blood‐brain barrier (BBB) is a selectively permeable barrier made up of tight junctions formed by endothelial cells that separates the circulating blood from the brain extracellular fluid. The primary function of the BBB is to limit the movement of xenobiotics from the blood to the brain. In the event of an ischemic stroke, the BBB opens allowing water and ions to enter the brain, leading to excitotoxicity and edema formation. Targeting such opening of the barrier following ischemic stroke has become a focus in current stroke studies. It has been shown that the Wnt/b‐catenin pathway is important for barrier formation during embryonic development, therefore, we hypothesized that activation of this pathway following ischemic stroke would attenuate barrier dysfunction. Brain microvascular endothelial cells (BMECs) derived from iPSCs were cultured and placed in ischemic stress for 6hrs, followed by an 18‐hour period of re‐oxygenation. Wnt small molecule activators (CHIR99021 and SB‐216763) and inhibitors (XAV939, IWP‐4, IWR‐1) were introduced at different time points of differentiation, during ischemia, and during re‐oxygenation. Transendothelial Electrical Resistance (TEER) and permeability were performed to assess barrier integrity following re‐oxygenation. For in vivo studies, C57BL mice were subjected to one‐hour ischemia by MCAO. At the time of re‐oxygenation, mice were dosed with CHIR99021 (IP; 30mg/kg). 24‐hours post‐MCAO, TTC staining on brains was performed to determine infarct size and edema ratio. The results of the in vitro studies have shown that activation of the Wnt pathway during re‐oxygenation results in increased barrier function, suggesting that the Wnt pathway is a potential target for post‐stroke therapy. This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .